Pasithea Therapeutics to present initial PAS-004 Phase 1/1b data
Pasithea Therapeutics says it will present initial PAS-004 clinical data from its ongoing Phase 1/1b trial in adult NF1 patients at the 2026 European Neurofibromatosis Conference.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.